Catalyst
Slingshot members are tracking this event:
Biohaven commences clinical testing of BHV-4157
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
This initial clinical trial will evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of BHV-4157. The study will explore a broad range of doses and results that will guide dosing in the upcoming randomized controlled trial of BHV-4157 in patients with spinocerebellar ataxia (SCA). Subject to these results, Biohaven plans to initiate a pivotal Phase III clinical trial in SCA before the end of the year.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 21, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Spinocerebellar Ataxia, Pivotal Phase Iii Clinical Trial
